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The novel human retrovirus xenotropic murine leukemia virus-related virus (XMRV) is arguably 
the most controversial virus of this moment. After its original discovery in prostate cancer tissue 
from North American patients, it was subsequently detected in individuals with chronic fatigue 
syndrome from the same continent. However, most other research groups, mainly from Europe, 
reported negative results. The positive results could possibly be attributed to contamination 
with mouse products in a number of cases, as XMRV is nearly identical in nucleotide sequence 
to endogenous retroviruses in the mouse genome. But the detection of integrated XMRV 
proviruses in prostate cancer tissue proves it to be a genuine virus that replicates in human 
cells, leaving the question: how did XMRV enter the human population? We will discuss two 
possible routes: either via direct virus transmission from mouse to human, as repeatedly seen 
for, e.g., Hantaviruses, or via the use of mouse-related products by humans, including vaccines. 
We hypothesize that mouse cells or human cell lines used for vaccine production could have 
been contaminated with a replicating variant of the XMRV precursors encoded by the mouse 
genome.
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How did XMRV enteR tHe HuMan population?
One of the most striking aspects of XMRV biology is the high 
sequence similarity to mouse chromosomal sequences that encode 
endogenous retroviruses. Initially, this raised the speculation that 
contamination with mouse DNA could explain the presence of 
XMRV in human samples. However, the absence of other mouse-
derived sequences, combined with the ease of infection of human 
cells with XMRV in vitro (Stieler et al., 2010), and the detection of 
integrated proviruses in prostate cancer tissues (Dong et al., 2007; 
Kim et al., 2008) indicated that laboratory contamination with 
mouse products is not a likely explanation for the origin of XMRV, 
at least for some of these studies. If contamination does not provide 
an explanation, where does the virus come from and how did it 
end up in humans?
Direct transmission of viruses from wild rodents to humans is 
not uncommon, e.g., rodent Hantaviruses and Arenaviruses spread 
through excrement via aerosols and are able to infect non-rodent 
species, including humans (Hart and Bennett, 1999; Klein and 
Calisher, 2007; Charrel and de Lamballerie, 2010). Transmission 
of xenotropic murine leukemia viruses (X-MLV’s) to humans is 
possible as human cells do express the XPR1 protein that is able 
to function as receptor for xenotropic and polytropic murine ret-
roviruses. The human XPR1 receptor protein shows a preference 
for xenotropic retroviruses, but is also able to mediate infection of 
polytropic murine leukemia retroviruses (P-MLV’s; Tailor et al., 
1999). Classical laboratory mice strains are hybrids between Mus 
musculus musculus, M. m. domesticus and M. m. castaneus, with 
around two-thirds of the genome coming from M. m. domesticus 
(Yang et al., 2007). X-MLV’s cannot (re-)infect most of the labora-
tory mouse strains due to polymorphisms in the XPR1 protein that 
disable xenotropic virus entry (Marin et al., 1999). Interestingly, 
the XPR1 genotype that prohibits X-MLV entry was not found 
intRoduction
The xenotropic murine leukemia virus-related virus (XMRV) is 
undoubtedly the most controversial human virus since its first 
detection in human samples in 2006 (Urisman et al., 2006). XMRV 
infection still lacks a firm disease association, although the virus 
was originally isolated from prostate cancer tissue and subsequently 
detected in the blood of American patients with chronic fatigue 
syndrome (CFS; Lombardi et al., 2009), and in the respiratory tract 
of patients with or without a respiratory tract infection (Fischer 
et al., 2010). However, irregular XMRV detection (Fischer et al., 
2008, 2010; Lombardi et al., 2009; Groom et al., 2010; Switzer et al., 
2010; van Kuppeveld et al., 2010) suggests that it is not likely to be 
a major causal factor. First, we do not know whether the biological 
reservoir has been investigated thus far, as most studies focused 
exclusively on blood or prostate tissue (summarized in Table 1). 
Second, some pathogenic retroviruses do not cause much of a 
viremia, and experimental infection of macaques suggests that this 
is also the case for XMRV (Sharma et al., 2010). In these monkeys, 
virus inoculation resulted in a low transient plasma viremia, fol-
lowed by a wide dissemination of replicating virus into various 
organs including spleen, lymph nodes, and gastrointestinal tract. 
Third, sequence variation may exist, but such variant virus strains 
could be missed by the PCR primers used.
Whether or not the virus causes disease in humans (reviewed 
extensively by Silverman et al., 2010, see also comments by Coffin 
and Stoye, 2009, by Kearney and Maldarelli, 2010, by Kaiser, 2010, 
and the cautionary note by Weiss, 2010), and how and when XMRV 
entered the human population – as the first Gammaretrovirus to 
do so – remains unclear. To add to the ongoing discussion, we 
would like to propose an alternative possible source for XMRV, 
human vaccines or other biological products that were produced 
in murine cells.Frontiers in Microbiology  |  Virology    January 2011  | Volume 1  | Article 147  |  2
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The ability of XPR1 to function as a receptor for xenotropic viruses 
was found to depend on the identity of two amino acid residues 
(Marin et al., 1999).
tHe oRigin of XMRV?
Every mouse genome contains multiple copies of endogenous 
MLV and has thus the capacity to express viral RNA and possibly 
viral particles. Endogenous MLV transcription has been described 
for many tissues and several mouse strains. It remains unclear if 
and when virus particles are generated and whether these parti-
cles are actually excreted. Zoonotic transmission of these viruses 
in wild-caught M. m. domesticus, suggesting that it is a rare allele 
(Baliji et al., 2010). Indeed, extensive screening identified seven 
strains of laboratory mice strains containing a permissive allele, of 
which at least three were susceptible to X-MLV and XMRV in cell 
culture (Baliji et al., 2010). In addition, the F/St mouse strain also 
produced infectious X-MLV together with a life-long viremia (Baliji 
et al., 2010). Many feral mice species, e.g., M. dunni and M. spretus, 
are also susceptible to infection with X-MLV’s (Battini et al., 1999; 
Marin et al., 1999; Tailor et al., 1999). Evidence on M. m. castaneus 
is conflicting, with some reporting a non-functional and others a 
susceptible XPR1 phenotype (Marin et al., 1999; Yan et al., 2010). 
Table 1 | XMRV prevalence and geography.
Country  Patient group  No. of  XMRV   Sample type  Reference 
    individuals  prevalence            
    tested  %
USA  CFS  101  67  Blood  Lombardi et al. (2009)
  Healthy controls  218  3.7   
USA  CFS  51  0  Blood  Switzer et al. (2010)
  Healthy controls  56  0   
USA  Prostate cancer  164  1.5–40  Prostate tissue  Urisman et al. (2006)
USA  Prostate cancer  40  15–40   Prostate tissue  Arnold et al. (2010)
USA  Prostate cancer  30  0  Prostate tissue  Sfanos et al. (2008)
USA  Prostate cancer  144  22  Prostate tissue  Danielson et al. (2010)
USA  HIV-infected  562  0  Blood  Kunstman et al. (2010)
  At risk for HIV infection  434  0   
USA  Various, including CFS and  293  0  Blood  Henrich et al. (2010) 
  HIV-infected
USA  Autism spectrum disorder  134  0  Blood  Satterfield et al. (2010)
Italy  (Healthy) controls  204  0   
  Autism spectrum disorder  96  0   
Mexico  Prostate cancer  55  0  Prostate tissue  Martinez-Fierro et al. (2010)
  Prostate hyperplasia  75  1.3   
Germany  Prostate cancer  87  0.4  Prostate tissue  Fischer et al. (2008)
  Benign prostate hyperplasia  70  1.4   
Germany  RTIa  267  2.3–9.9  Respiratory (sputum,   Fischer et al. (2010) 
      BAL, nasal swab)
  Healthy controls  62  3.2   
UK  CFS  186  0  Blood  Erlwein et al. (2010)
UK  CFS  170  0  Blood  Groom et al. (2010)
  Healthy controls  395  0   
UK/Switzerland  HIV/HCV infected risk groups  230  0  Blood  Barnes et al. (2010)
France  Children with RTIa,b  142  0  Blood/respiratory/  Jeziorski et al. (2010) 
      bone marrow
  Adults with spondyloarthritis  19  0   
The Netherlands  CFS  32  0  Blood  van Kuppeveld et al. (2010)
  Healthy controls  43  0   
The Netherlands  HIV-infected men  54  0  Seminal plasma  Cornelissen et al. (2010)
The Netherlands  Prostate cancer  74  4  Prostate tissue  Verhaegh et al. (2010)
Denmark  Multiple sclerosis   50  0  Blood  Maric et al. (2010)
China  CFS  65  0  Blood  Hong et al. (2010)
  Healthy controls  85  0   
aRespiratory tract infection.
bOther hematological, neurological, or inflammatory pathologies.www.frontiersin.org  January 2011  | Volume 1  | Article 147  |  3
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defective endogenous proviruses. Recombination can also extend 
the viral host range (cell type and/or host species). A virus carry-
ing a xenotropic env gene is more infectious for human cells as 
the human XPR1 protein has a preference for xenotropic murine 
envelope proteins over polytropic ones. The replication-competent 
endogenous cat retrovirus RD-114 is an example of a recombinant 
virus expressed from endogenous sequences. It combines FcEV gag–
pol genes (FcEV is an endogenous retrovirus of cats) and a BaEV 
env gene (BaEV is an endogenous retrovirus of African monkeys)   
(van der Kuyl et al., 1999). RD-114 is expressed by all species of the 
genus Felis, but not in other felines, and probably originates from 
a cross-species transmission of BaEV, followed by a recombination 
event and subsequent germ-line integration.
aRe Mouse-deRiVed biological pRoducts tHe souRce 
of XMRV?
Detection rates of XMRV in populations are extremely variable, with 
0–67% positivity in patients and 0–3.7% in healthy controls (Fischer 
et al., 2008, 2010; Lombardi et al., 2009; Groom et al., 2010; Switzer 
et al., 2010; van Kuppeveld et al., 2010), suggesting that virus preva-
lence and thus exposure could vary significantly with geographic loca-
tion. Although the virus could possibly be transmitted from feral mice 
to humans in a natural setting, followed by a rapid dissemination in 
the human population, the high XMRV sequence similarity on two 
continents would suggest an alternative transmission route. Likely 
sources of XMRV are mouse-derived products. Some mouse genomes 
encode complete copies of X-MLV’s with at least 92% similarity to 
XMRV; segments with even higher homology are present on other 
locations, and could result in novel recombinant viruses. So, X-MLV’s 
that closely resemble XMRV could then be produced from these loci 
and virions could be excreted from mouse tissue or cell cultures.
aRe X-MlV’s pRoduced in Mice?
MLV’s, including xenotropic sequences, are actively transcribed 
in mouse brain (Kwon et al., 2008), and mice can produce virus 
particles of different MLV classes (Ribet et al., 2008). In vivo recom-
bination between endogenous and exogenous polytropic MLV’s 
has also been reported, resulting in viable viral offspring capable 
of infecting a variety of species (Evans et al., 2009). The Bxv1 locus 
in M. musculus molossinus is an example of an endogenous xeno-
tropic/polytropic recombinant MLV that is expressed and gives 
rise to a life-long viremia in laboratory mice of the F/St strain 
(Baliji et al., 2010).
Although there was no evidence of X-MLV transmission to human 
embryonic stem cells expressing XPR1 after cocultivation with murine 
cells expressing X-MLV particles in a single report (Amit et al., 2005), 
this does not imply that transmission may not have occurred on 
another occasion. The prostate carcinoma cell line 22Rv1 is a popular 
research tool because it contains approximately 10 integrated cop-
ies of the XMRV provirus and it produces infectious virus (Knouf 
et al., 2009). The origin of the 22Rv1 cell line may represent a recent 
transmission case as a carcinoma was grafted in nude mice to estab-
lish this permanent cell line (Sramkoski et al., 1999). The complete 
22Rv1 provirus has 99% sequence similarity with other XMRV iso-
lates (Paprotka et al., 2010). Possibly, the 22Rv1 carcinoma cells were 
infected with XMRV by mouse cells surrounding the tumor graft 
(Knouf et al., 2009).
could have occurred in the many million years that mice and men 
have shared the same environment. But current XMRV sequences 
isolated from human samples do closely mimic mouse genomic 
sequences, thus suggesting a low number of replication cycles 
since zoonotic transmission, which is thus likely to have occurred 
recently. The mutation rate of MLV’s is not different from other 
retroviruses (Sanjuan et al., 2010; although its replication rate 
may be low), implying that if the transmission had taken place a 
long time ago, more nucleotide substitutions should have become 
fixed. Phylogenetic sequence analysis, however, revealed very short 
branches for XMRV and the mouse xMERV sequences on chromo-
somes 7 and 9, indicating that very few mutations have occurred 
since transmission (Urisman et al., 2006; Fischer et al., 2008, 2010). 
In addition to the loci on chromosomes 7 and 9, a BLAST search 
using the NCBI sequence database1 retrieves loci on mouse chro-
mosomes 4, 11, and 12 with a much higher (98–100%) sequence 
identity to XMRV-gag nucleotide sequences (e.g., GenBank acces-
sion  numbers AC124739, AY349138,  and AL627314).  Blasting 
whole genome XMRV sequences recovers very similar sequences 
with large stretches of sequence identity on mouse chromosomes 4, 
5, 13, and Y, especially for the 3′ end of the XMRV genome. These 
results suggest that the genome of human XMRV is present, albeit 
in two parts, in the mouse genome with effectively no nucleotide 
changes. Even in slowly evolving retroviruses like foamy viruses, 
100% sequence identity is only seen in animals with close contact 
or humans that have been bitten by an infected primate, suggestive 
of direct transmission, while intraspecies variation is generally 
around 85–95% for the pol gene (Switzer et al., 2004; Calattini 
et al., 2006; Liu et al., 2008).
A recently described locus (Baliji et al., 2010) on chromosome 1 
of M. musculus (GenBank accession number AC115959) contains 
a provirus that is 92% homologous to XMRV from the 22Rv1 cell 
line (GenBank accession number FN692043) over its complete 
genome length. This provirus, Bxv1, is mainly found in Japanese 
M. molossinus (a natural hybrid of M. castaneus and M. musculus) 
and is highly expressed in some laboratory mouse strains (Baliji 
et al., 2010). However, the Bxv1 provirus is less likely to be the 
source of XMRV, as its similarity to XMRV is much lower than 
that of other murine loci.
XMRV is a noVel RecoMbinant RetRoViRus
Xenotropic  murine  leukemia  virus-related  virus  is  actually  a 
recombinant virus, resembling polytropic-endogenous sequences 
for the 5′ half up to approximately the middle of the pol gene and 
xenotropic-endogenous sequences for the 3′ half of the genome, 
which includes the env gene (see: Courgnaud et al., 2010). This 
recombination event is likely to have occurred in the mouse before 
transmission to humans. At least one recombinant provirus, Bxv1, 
is already found in the M. musculus genome (Baliji et al., 2010). 
This locus is heterogeneous in subspecies of M. musculus, suggest-
ing that it represents a recent integration. Recombination rates 
are high for all retroviruses because they package two copies of 
the RNA genome in virions, which drives subsequent mixing of 
sequences during the reverse transcription process. Recombination 
also enables the generation of replication-competent viruses from 
1http://blast.ncbi.nlm.nih.gov/Blast.cgiFrontiers in Microbiology  |  Virology    January 2011  | Volume 1  | Article 147  |  4
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  generated in mice could possibly be polluted by XMRV and related 
viruses. Platinum Taq polymerase from Invitrogen Corporation, 
prepared using mouse monoclonal antibodies, is known to be fre-
quently contaminated with mouse DNA, which can generate false-
positive PCR amplifications in combination with X-MLV or XMRV 
primers (Erlwein et al., 2010a). It is less likely that monoclonal 
antibodies from mice are a major source of XMRV in the human 
population as they are in use only recently, but they could provide 
a future supply of mouse-derived viruses. Although monoclonals 
are treated with detergents before use in patients, virus inactiva-
tion may not be complete, especially as protein function should be 
conserved. And if retroviral particles containing RNA genomes are 
copurified with the antibody proteins, the absence of mouse DNA 
may give a false impression of safety.
XMRV contaMination of cell lines?
It is possible that XMRV particles were present in virus stocks 
cultured in mice or mouse cells for vaccine production, and that 
the virus was transferred to the human population by vaccina-
tion. The sequence homogeneity of all XMRV isolates known 
today suggests that only a single or very few transmissions have 
occurred, which is consistent with the proposed vaccination route. 
Nowadays, vaccine batches are carefully checked with sensitive 
PCR assays for the presence of contaminating retroviruses, but 
this screening was not performed in the early years of vaccination 
(Trijzelaar, 1993 see also Miyazawa et al., 2010). Apart from vac-
cines, other biological products have been generated using mice 
or mouse cells. Alternatively, laboratory contamination with a 
mouse-derived virus of cell lines used for, e.g., vaccine produc-
tion could have occurred (Hartley et al., 2008; Takeuchi et al., 
2008; Stang et al., 2009). The virus could then unintentionally 
have been transmitted to the human population. Nowadays, many 
vaccine strains are grown in human diploid cell lines (Fletcher 
et al., 1998), which are susceptible to MLV infection. A recent 
report detected other MLV-related sequences in CFS patients and 
healthy controls from North America (Lo et al., 2010), suggesting 
that more MLV strains may have been transmitted to the human 
population, possibly in a similar fashion. However, solid evidence 
that these polytropic MLV sequences represent replicating virus 
is currently lacking.
wHeRe was XMRV tRansMitted?
Xenotropic murine leukemia virus-related virus was found in 
samples from CFS patients in North America, but not in Europe. 
The virus was detected in prostate cancer tissue from patients 
on both continents. There is a single report with negative results 
from China (Hong et al., 2010), and a single report with one posi-
tive sample from Mexico (Martinez-Fierro et al., 2010) but none 
from other areas of the world, leaving many questions about the 
true distribution of XMRV in humans. Prevalence of XMRV from 
North American studies varies between 3.7 and 67% in four stud-
ies with two other studies reporting negative results (one in CFS 
patients and healthy controls (Switzer et al., 2010), and one in HIV-
infected patients receiving antiretroviral therapy and untreated 
men at risk for HIV infection (Kunstman et al., 2010)). In Europe, 
XMRV was detected in two studies from Germany (Fischer et al., 
2010), and in one from The Netherlands (Verhaegh et al., 2010), 
Vaccines, ViRuses, and contaMination
One of the most widely distributed biological products that fre-
quently involved mice or mouse tissue, at least up to recent years, 
are vaccines, especially vaccines against viruses. Some, for instance 
vaccines against rabies virus (Plotkin and Wiktor, 1978), yellow 
fever (YF) virus (Frierson, 2010), and Japanese encephalitis (JE) 
virus (Inactivated Japanese Encephalitis Virus Vaccine, 1993), con-
sisted of viruses that were cultured on mouse brains. Such vaccines 
were in use from 1931 (YF vaccine) until now (JE vaccine, licensed 
in Japan since 1954). For rabies virus, early vaccines were mainly 
of goat or sheep nerve tissue origin. In addition, suckling mouse 
brain-derived rabies virus vaccines were used in South America and 
France (Plotkin and Wiktor, 1978). No mouse-derived rabies vac-
cine was ever licensed in the USA (Dennehy, 2001). Live-attenuated 
YF vaccines were originally also grown on mouse brain, but an YF 
vaccine grown on chicken eggs (named 17D) became available in 
1937, and was since the vaccine of choice in the America’s. In 1962, 
contamination of the 17D vaccine with oncogenic avian leukosis 
virus was detected both in England and in the USA, but fortu-
nately no excess of cancer incidence among vaccines was reported 
(Frierson, 2010). In France, the mouse brain-derived YF vaccine 
was discontinued as late as 1982.
Although being the most effective means to prevent infectious 
diseases and to safe lives, serious contamination problems involv-
ing vaccines have occurred (Pastoret, 2010). Contamination with 
unrelated viruses such as the presence of hepatitis B virus (HBV) in 
YF vaccine preparations stemming from the use of human serum 
for stabilization, and simian virus 40 (SV40) and foamy viruses 
through the use of monkey cell cultures (Pastoret, 2010). Some 
vaccine viruses are inactivated before use, hopefully also inactivat-
ing any contaminating virus particles, but the contaminating virus 
may be more stable than the vaccine virus. For instance, SV40 is 
highly resistant to inactivation (Murray, 1964). Endogenous retro-
viruses constitute a distinct class of contaminating viruses, as these 
viruses are encoded by all cells of a certain species, and therefore 
cannot be avoided even through rigorous screening (Miyazawa, 
2010). Contamination with endogenous avian leukosis viruses is 
a major problem for vaccine viruses grown in chicken embryos or 
chicken embryonic fibroblasts (Hussain et al., 2003). Infectious 
cat endogenous RD-114 virus has been found in several veteri-
nary vaccines produced in cat cell cultures (Miyazawa et al., 2010; 
Yoshikawa et al., 2010).
XMRV and Monoclonal antibodies
Apart from vaccines, other mouse-derived biologicals could have 
been a source of XMRV in the human population. Monoclonal anti-
bodies present a modern treatment for many cancers and other dis-
eases including cardiovascular disease, psoriasis, and auto-immune 
disorders (for a review see: Stern and Herrmann, 2005). The first 
monoclonal antibody, OKT3 (to be used against transplant rejec-
tion), was approved by the FDA in 1986. The market for monoclonal 
antibody therapy has been expanding rapidly after the year 2000. 
Initially, murine antibodies produced by the hybridoma technique 
were used (Kohler and Milstein, 1975), but these have been largely 
abandoned because of (sometimes severe) allergic reactions. The 
murine antibodies were often replaced by humanized antibod-
ies mainly produced in transgenic mice. Monoclonal antibodies www.frontiersin.org  January 2011  | Volume 1  | Article 147  |  5
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was initially proposed (Hong et al., 2009), but XMRV was not 
detected in seminal plasma from HIV-infected men (Cornelissen 
et al., 2010). The detection of XMRV fragments in the respira-
tory tract (Fischer et al., 2010) suggests that the virus may be 
transmitted by saliva, although RNA concentrations were low. 
Transmission through saliva, mainly by biting, has been reported 
for most retrovirus genera, including ecotropic MLV’s (Portis 
et al., 1987). Another major threat is transmission through blood 
products as infectious virus has been cultured from blood cells 
(Lombardi et al., 2009).
Up till now, all patients with detectable XMRV have been adults, 
the majority of them middle-aged or older (mean ± 55 years). A 
study in 142 children with a diversity of pathologies, including 
respiratory diseases in France revealed no XMRV infections in that 
age group (Jeziorski et al., 2010), although the incidence of XMRV 
in France is not known. Another study in autistic children from the 
USA and Italy was also negative for XMRV (Satterfield et al., 2010). 
XMRV can likely be acquired at any age, and then probably estab-
lishes a chronic, latent infection like other retroviruses. Therefore 
the age of XMRV-infected individuals does not provide an unam-
biguous clue about when XMRV entered the human population.
conclusion
In conclusion, the most likely mode of XMRV transmission points 
to mouse-derived biological products, but it cannot formally be 
excluded that the virus was once transferred from feral mice 
to humans. The latter scenario is less likely as it would imply 
that a very rapid spread in the human population must have 
occurred to explain its presence on two continents. In this sce-
nario, the extreme sequence similarity among XMRV genomes, 
both between and within individuals, would argue that the virus 
replicates at very low levels. Among the biological products, vac-
cines that were produced in mice or mouse cells are possible 
candidates that warrant further inspection. If XMRV was intro-
duced in the human population through the use of biologicals, a 
background level of the virus in the human population, possibly 
varying with geography or age group, would be expected. Such a 
low level presence would then also explain the (absence of) detec-
tion of the virus in different studies, as well as its controversial 
association with disease.
We hope that this hypothesis will spur further discussion and 
help to resolve the many remaining XMRV questions.
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but not in the UK (Erlwein et al., 2010b; Groom et al., 2010), 
France (Jeziorski et al., 2010), Denmark (Maric et al., 2010), and 
two other studies from The Netherlands (Cornelissen et al., 2010; 
van Kuppeveld et al., 2010), although the nature of the samples 
analyzed differed between studies. Table 1 summarizes the results 
from these studies.
Xenotropic murine leukemia virus-related virus sequences 
from Germany and North America exhibit very little nucleotide 
divergence, suggesting that they descended from a common ances-
tor relatively recently. A close inspection of the phylogenetic trees 
obtained with XMRV-gag sequences (Fischer et al., 2008, 2010) 
suggests that XMRV sequences from the USA are closer to the 
common ancestor than German XMRV sequences, although the 
trees are not optimal due to the high sequence conservation. Being 
closer to the most recent common ancestor (MRCA) is suggestive 
of an older virus. Possibly, XMRV was transmitted from mice 
to men in the USA, and soon after this event introduced into 
Germany. Germany had close connections with the USA after 
World War II, with large numbers of military personnel (and 
their families) stationed in Germany from 1945 till present times. 
In 2006, there were still 57.080 American army employees dis-
tributed over more than 200 locations in Germany, mainly in the 
south and west of the country2. US military personnel are highly 
vaccinated, e.g., virtually all recruits were vaccinated with YF vac-
cine in 1941–1942 after the outbreak of World War II (Frierson, 
2010). A massive outbreak of jaundice, with at least 26,000 cases 
in the Western region of the USA, was due to the use of human 
serum contaminated with HBV in the vaccine (see Frierson, 2010). 
Recently, massive smallpox vaccination of the US army person-
nel has been carried out (Grabenstein and Winkenwerder, 2003). 
XMRV-infected Americans could subsequently have introduced 
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